BANF1 and atherosclerosis: Since reducing the death of foam cells and SMCs is a therapeutic goal to prevent atherosclerosis development and worsening and to stabilize the lesion cap [128,129], in vivo BANF1 upregulation could have a role in decelerating foam cells and SMC death and in reducing plaque instability.